Skip to main content
No.1 Press Release Service in Korea
Search
Search
Login
Create Account
Services
Contact Us
News
Services
About Us
Contact Us
Korean
News
All News
News by Region
Korea
Overseas
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Services
Why Korea Newswire?
How We Distribute
Services & Pricing
Basic
Standard
Premium
Global
Translation
Press Release Network in Korea
Korean Language
About Us
News
Services
Contact Us
Search
Cancel
Search
Submit Press Release
Latest News
News by Region
Korea
World
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Health News Releases
Today April 26
February 28, 11:50
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=53900859&newsitemid=20240226047170&lan=en-US&anchor=BeiGene&index=1&md5=9fa7f0cbddab2bafa454d24c749
February 25, 10:15
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Celltrion today presented positive two-year results from the extended LIBERTY studies (LIBERTY-CD1 and LIBERTY-UC2) in patients with moderately to severely active Crohn’s disease (CD) and ulcerative c
February 23, 17:35
New Swiss Made Features for Cataract Surgery Lens Selection
The company Swiss Advanced Vision (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsav-iol.com%2F&esheet=53899982&newsitemid=20240222791326&lan=en-US&anchor=Swiss+Advanced+Vision&ind
February 23, 14:10
ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emer
February 22, 17:20
Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=53898438&newsitemid=20240221815046&lan=en-US&anchor=Parse+Biosciences&index=1&md
February 22, 15:35
MMI Raises $110 Million in Series C Financing
MMI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.mmimicro.com%2F&esheet=53897487&newsitemid=20240221774903&lan=en-US&anchor=MMI&index=1&md5=d18846e1e7a7c30d597fb199c3bb2d60)
February 21, 17:25
Sinovac Amends Shareholder Rights Plan
Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder righ
February 21, 13:45
AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review an
February 21, 09:30
MRM Health Initiates Clinical Research in Parkinson’s Disease
MRM Health, a clinical-stage biopharmaceutical company, announced today that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study
February 20, 10:10
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access t
February 18, 13:15
Patient Safety Movement Foundation Outlines 2024 Action Plan for Creating a Safer Healthcare System
At the Patient Safety Movement Foundation (https://psmf.org)’s annual Mid-Year Event on January 26, patient safety experts from around the world participated in the creation of an action plan to elimi
February 15, 10:30
HistoSonics Awarded Key Position in UK’s Novel Innovation Program
HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy platforms, announced today that the company’s Edison System has been selected to participate i
February 14, 16:24
CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
Correction by Galderma: Results from the OLYMPIA program demonstrated that more than half of nemolizumab-treated patients achieved an at least four-point reduction in itch intensity, as measured by th
February 11, 14:05
Newmont and Project C.U.R.E. - Two Decades of Partnership Delivering Global Medical Support
Newmont Corporation (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newmont.com%2Fhome%2Fdefault.aspx&esheet=53893580&newsitemid=20240208935869&lan=en-US&anchor=Newmont+Corporat
February 11, 11:15
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53894240&newsitemid=20240208344780&lan=en-US&anchor=TSE%3A4502%2FNYSE%
February 08, 15:32
Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
Cetaphil®, a leading dermatologist-recommended sensitive skincare brand, is launching a first-of-its-kind global skincare immersion. This immersion will put the sensitive skin science behind its formu
February 08, 14:00
Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib
February 07, 15:12
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep-dive into the global aesthetics trends set to shape 20
February 07, 11:15
Parse Biosciences Partners with INTEGRA Biosciences for Automated Single Cell Workflows
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plu
February 05, 17:40
TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydr
February 05, 14:40
Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting
February 04, 13:24
Located in Seoul, Korea, Topcon Korea Medical Co., Ltd. (TKM) Was Established and Formally Launched in 2023.
Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (hencef
February 04, 11:26
Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center
Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-
February 04, 11:00
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
We are excited to share our latest development status. As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lu
February 04, 10:51
Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare professionals and unmatched patient satisfaction. Sculpt
«
1
2
3
4
5
»
25 per page
25 per page
50 per page
75 per page
100 per page
Distribute Your News to
KOREA
The largest press release distribution network in Korea
34,000 journalists
7,000 media outlets
345 industry channel
80,000 subscribers
Get Started
Global PR service
Reach Your Target
Audience in 160 Countries
powered by
Get Started
News by region
Korea
Overseas
News by industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Notice